Interprofessional Perspectives on Managing Immune-Related Adverse Events

Target Audience
This activity will reach the interprofessional care team of physicians, nurses and pharmacists who care for patients undergoing immunotherapy treatments.

Program Overview
The development of immunotherapies, including ICIs and CAR-T cell agents, is improving survival for some patients with cancer, even in advanced cases. These agents are associated with novel irAEs that are monitored and managed differently than the more familiar standard chemotherapy toxicities. Collaboration among members of the oncology care team is necessary to ensure that all healthcare providers, patients, and caregivers are educated about irAEs and their management. For all members of the team to support optimal outcomes, clinicians need to continue to enhance their knowledge and skills regarding the latest guidelines and treatment.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Describe key processes that underlie immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICIs) or chimeric antigen receptor T-cell (CAR-T) therapy
Identify early signs of novel irAEs associated with ICIs and CAR-T therapies
Apply guideline-recommended strategies for monitoring and managing novel irAES associated with ICIs and CAR-T therapy
Educate patients and caregivers to recognize early signs of irAEs in patients treated with ICIs or CAR-T therapies and when to seek medical attention
Improve clinician confidence in managing irAEs through interprofessional collaboration